^
    Back
    Association details:
    Biomarker:MYD88 L265P
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Zhonghua Bing Li Xue Za Zhi
    Title:

    [Lymphoplasmacytic lymphoma: a clinicopathological and prognostic analysis of 27 cases]

    Published date:
    12/08/2021
    Excerpt:
    Twenty-seven cases of LPL from January 2016 to December 2020 at Guangdong Provincial People's Hospital were collected...The positive rate of MYD88 L265P mutation was 73.9% (17/23). Most of the patients were treated with rituximab...Most of the patients were treated with rituximab combined with alkylating agents, nucleoside analogues or immunomodulators, and the few patients with relapse or progression...
    Secondary therapy:
    Alkylating agent; Nucleoside analog; Immunomodulator
    DOI:
    10.3760/cma.j.cn112151-20210316-00208